ES556684A0 - Un procedimiento para tratar celulas efectoras que tienen receptores de superficie para la region fc de un anticuerpo - Google Patents

Un procedimiento para tratar celulas efectoras que tienen receptores de superficie para la region fc de un anticuerpo

Info

Publication number
ES556684A0
ES556684A0 ES556684A ES556684A ES556684A0 ES 556684 A0 ES556684 A0 ES 556684A0 ES 556684 A ES556684 A ES 556684A ES 556684 A ES556684 A ES 556684A ES 556684 A0 ES556684 A0 ES 556684A0
Authority
ES
Spain
Prior art keywords
antibody
procedure
region
surface receptors
treating effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES556684A
Other languages
English (en)
Other versions
ES8800981A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gary R Landucci (titular Al 50%)
Original Assignee
University of Minnesota Twin Cities
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota Twin Cities, University of Minnesota System filed Critical University of Minnesota Twin Cities
Publication of ES8800981A1 publication Critical patent/ES8800981A1/es
Publication of ES556684A0 publication Critical patent/ES556684A0/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
ES556684A 1985-06-28 1986-06-25 Un procedimiento para tratar celulas efectoras que tienen receptores de superficie para la region fc de un anticuerpo Expired ES8800981A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75009185A 1985-06-28 1985-06-28

Publications (2)

Publication Number Publication Date
ES8800981A1 ES8800981A1 (es) 1987-12-01
ES556684A0 true ES556684A0 (es) 1987-12-01

Family

ID=25016458

Family Applications (1)

Application Number Title Priority Date Filing Date
ES556684A Expired ES8800981A1 (es) 1985-06-28 1986-06-25 Un procedimiento para tratar celulas efectoras que tienen receptores de superficie para la region fc de un anticuerpo

Country Status (13)

Country Link
EP (1) EP0227809B1 (es)
JP (1) JPS62503144A (es)
CN (1) CN86104913A (es)
AT (1) ATE80802T1 (es)
AU (1) AU597265B2 (es)
CA (1) CA1341303C (es)
DE (1) DE3686811D1 (es)
DK (1) DK107787D0 (es)
ES (1) ES8800981A1 (es)
HU (1) HUT43495A (es)
IL (1) IL79260A (es)
WO (1) WO1987000054A1 (es)
ZA (1) ZA864769B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192537A (en) * 1984-03-30 1993-03-09 Cellcor Inc. Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US4863726A (en) * 1987-05-29 1989-09-05 Cetus Corporation Combination therapy using immunotoxins with interleukin-2
AU2925789A (en) * 1987-12-17 1989-07-19 Browning's Clinical Pathology Services Limited Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection
US5834441A (en) * 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
US6652850B1 (en) 1993-09-13 2003-11-25 Aventis Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
US20020168347A1 (en) * 1998-04-09 2002-11-14 Jacques Bartholeyns Use of monocytes derived cells, antigens and antibodies for optimal induction of immunotherapeutic efficiency
AU3601299A (en) * 1998-04-09 1999-11-01 I.D.M. Immuno-Designed Molecules Use of monocytes derived cells and antibodies in a synergic way for optimal induction of immunotherapeutic efficiency
US6868665B2 (en) 2001-12-21 2005-03-22 General Electric Company Methods and apparatus for operating gas turbine engines
US7200538B2 (en) 2003-01-15 2007-04-03 General Electric Company Methods and apparatus for modeling gas turbine engines

Also Published As

Publication number Publication date
ZA864769B (en) 1987-02-25
IL79260A0 (en) 1986-09-30
EP0227809B1 (en) 1992-09-23
CN86104913A (zh) 1987-05-27
ATE80802T1 (de) 1992-10-15
HUT43495A (en) 1987-11-30
IL79260A (en) 1990-11-29
ES8800981A1 (es) 1987-12-01
DK107787A (da) 1987-03-02
AU597265B2 (en) 1990-05-31
JPS62503144A (ja) 1987-12-17
DK107787D0 (da) 1987-03-02
EP0227809A4 (en) 1987-10-19
CA1341303C (en) 2001-10-09
DE3686811D1 (de) 1992-10-29
AU6125486A (en) 1987-01-30
EP0227809A1 (en) 1987-07-08
WO1987000054A1 (en) 1987-01-15

Similar Documents

Publication Publication Date Title
NL300353I1 (nl) Geneesmiddelen met monoclonale antilichamen, die specifiek zijn voor de menselijk epidermale groeifactorreceptor
ES521422A0 (es) Procedimiento para la obtencion de derivados de carboxilamida n-glicosilados.
AU7697301A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
GR3026219T3 (en) Mouse monoclonal antibodies
WO1990014067A3 (en) Methods for treating anxiety with sigma receptor ligands
DE3789082D1 (de) Expression eines tumorspezifischen Antigens eines rekombinanten Virusvektors sowie dessen Anwendung zur versorgenden oder heilenden Behandlung des entsprechenden Tumors.
RU92016354A (ru) Композиция, способы лечения, способ предупреждения рецидива, способ усиления цитотоксической активности иммунотоксина, способ усиления цитотоксического действия конъюгата
NZ210867A (en) Tumour-specific monoclonal antibodies, production thereof and use
ES556684A0 (es) Un procedimiento para tratar celulas efectoras que tienen receptores de superficie para la region fc de un anticuerpo
NZ237688A (en) Antibody-cytotoxic immunoconjugate-containing compositions and cancer treatment
PT88157A (pt) Antigenes d'excretion-secretion specifiques de toxoplasma gondii leurs produits d'expression leurs procedes d'obtention et leurs applications diagnostiques et prophylactiques
PT81093B (pt) Processo para a preparacao de uma composicao terapeutica para tratamento de um tumor
KR890700353A (ko) 면역독소의 면역억제 기저 사람치료법
PT73950A (fr) Procede de preparation de composes de dichloredietilaminopheni-lalanine d'action antitumureuse
WO1999065517A3 (en) Therapeutic compositions that produce an immune response by altering the antigen
IL101675A (en) Method and pharmaceutical compositions for detecting and localizing tissues having neurokinine 1 receptors
DE69942637D1 (de) Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
ZA884777B (en) Antigen recognized by mca 16 88

Legal Events

Date Code Title Description
PC1A Transfer granted

Owner name: GARY R. LANDUCCI (TITULAR AL 50%)